Apitope News

Latest Press Releases

Apitope Announces Management Changes

October 24, 2018

Keith Martin to retire as CEO, continue as Non-Executive DirectorHayley French appointed COO and interim CEO HASSELT, Belgium, and CHEPSTOW, UK, 24 October 2018 – Apitope, a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapies targeting autoimmune diseases, today announces that Chief Executive Officer (CEO) Dr Keith Martin has decided to retire from the…

Details

Apitope Announces Publication of Graves’ Disease Data in International Peer-Reviewed Journal, Endocrinology

August 14, 2018

HASSELT, Belgium, and CHEPSTOW, UK, 14 August 2018 – Apitope, a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapies targeting autoimmune diseases, today announces publication of its pre-clinical Graves’ disease data in Endocrinology, one of the leading peer-reviewed endocrinology medical journals. The publication entitled: Immunotherapy with apitopes® blocks the immune response to thyroid stimulating…

Details

Apitope announces positive results with novel treatment for Graves’ disease

April 16, 2018

Phase I data show early efficacy in the majority of patients and a very favourable safety profile HASSELT, Belgium, and CHEPSTOW, UK, 16 April 2018 – Apitope, a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapies targeting autoimmune diseases (including multiple sclerosis (MS), Graves’ disease and uveitis), today announced positive results from the Phase…

Details

Apitope Announces Publication of Data in International Peer-Reviewed Journal Neurology on Novel Multiple Sclerosis Therapy

March 19, 2018

HASSELT, Belgium, and CHEPSTOW, UK, 19 March 2018 – Apitope, a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapies targeting autoimmune diseases, today announced publication of data on it multiple sclerosis treatment in Neurology, the official journal of the American Academy of Neurology and one of the world’s most widely read and highly cited…

Details

Apitope Strengthens Board with Senior Appointment

March 7, 2018

Dr William Jenkins appointed as Independent Non-Executive Director Recent board roles include Ablynx, BTG, Evotec

Details

Apitope announces positive ATX-MS-1467 phase IIa data in relapsing Multiple Sclerosis

February 21, 2017

Hasselt, Belgium and Chepstow, UK: 21 February 2017 − Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, announces positive results from the Phase IIa clinical study of its lead product candidate, ATX-MS-1467, for the treatment of patients with multiple sclerosis. The Phase IIa, open-label, one arm study…

Details